Skip to main content
SpringerLink
Log in
Book cover

Aktuelles aus Klinik und Praxis der Urologie pp 11–30Cite as

Multimodale Therapie des Prostatakarzinoms

  • Chapter
  • First Online:

  • 1343 Accesses

Part of the book series: WissenKompakt Medizin ((WISSKOMED))

Zusammenfassung

Ein Viertel der jährlich in Deutschland neu diagnostizierten Krebserkrankungen sind urologische Tumoren, deren Behandlung zunehmend komplexer und interdisziplinärer wird. Um Erkenntnisse aus der molekularbiologischen Forschung unmittelbar anwenden und in Therapiestudien umsetzen zu können, sind nach US-amerikanischem Vorbild auch in Deutschland Krebszentren, sog. Comprehensive Cancer Center, entstanden, in denen Forschungslaboratorien und Kliniken eng zusammenarbeiten. Am Beispiel des Prostatakarzinoms soll exemplarisch dargestellt werden, wie aktuell neue Erkenntnisse aus der molekularen und translationalen Forschung in neue Behandlungsansätze umgesetzt werden. Dabei ist das Stichwort der multimodalen Diagnostik und Therapie, d. h. eine Kombination verschiedener, zum Teil komplementärer Ansätze zur Erkennung und Behandlung des Tumors, aktuell von größter Bedeutung. Neben Definition des Prostatakarzinoms, Darstellung des Gleason-Scores und des Epstein-Gradings sollen die für den Therapiealgorithmus relevanten Risikoklassifikationen vorgestellt werden.

This is a preview of subscription content, log in via an institution.

eBook
USD   9.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   17.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Literatur

  1. Hadaschik B et al (2013) Urology in the concept of comprehensive cancer centers. Urologe A 52(9):1283–1289

    Article  Google Scholar 

  2. Rothke M et al (2013) PI-RADS classification: structured reporting for MRI of the prostate. Rofo 185(3):253–261

    Article  Google Scholar 

  3. Omlin A, Gillessen S (2012) Inhibitors of androgen and estrogen biosynthesis in castration-resistant prostate cancer. Urologe A 51(1):8–14

    Article  Google Scholar 

  4. Holmberg L et al (2002) A randomized trial comparing radical prostatectomy with watchful waiting in early prostate cancer. N Engl J Med 347(11):781–789

    Article  Google Scholar 

  5. Bill-Axelson A et al (2014) Radical prostatectomy or watchful waiting in early prostate cancer. N Engl J Med 370(10):932–942

    Article  Google Scholar 

  6. Bratt O, Loman N (2015) Clinical management of prostate cancer in men with BRCA mutations. Eur Urol 68(2):194–195

    Article  Google Scholar 

  7. Castro E et al (2015) Effect of BRCA mutations on metastatic relapse and cause-specific survival after radical treatment for localised prostate cancer. Eur Urol 68(2):186–193

    Article  Google Scholar 

  8. Bellefqih S et al (2016) Combined radiation therapy and androgen deprivation in the management of prostate cancer: Where do we stand? Cancer Radiother 20(2):141–150

    Article  Google Scholar 

  9. Miyamoto H, Rahman MM, Chang C (2004) Molecular basis for the antiandrogen withdrawal syndrome. J Cell Biochem 91(1):3–12

    Article  Google Scholar 

  10. Stewart SB, Boorjian SA (2015) Radical prostatectomy in high-risk and locally advanced prostate cancer: Mayo Clinic perspective. Urol Oncol 33(5):235–244

    Article  Google Scholar 

  11. Lee BH et al (2015) Are biochemical recurrence outcomes similar after radical prostatectomy and radiation therapy? Analysis of prostate cancer-specific mortality by nomogram-predicted risks of biochemical recurrence. Eur Urol 67(2):204–209

    Article  Google Scholar 

  12. Sundi D et al (2014) Identification of men with the highest risk of early disease recurrence after radical prostatectomy. Prostate 74(6):628–636

    Article  Google Scholar 

  13. Briganti A et al (2014) Prediction of outcome following early salvage radiotherapy among patients with biochemical recurrence after radical prostatectomy. Eur Urol 66(3):479–486

    Article  Google Scholar 

  14. Abdollah F et al (2014) Impact of adjuvant radiotherapy on survival of patients with node-positive prostate cancer. J Clin Oncol 32(35):3939–3947

    Article  Google Scholar 

  15. Scher HI et al (2008) Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol 26(7):1148–1159

    Article  Google Scholar 

  16. Eichholz A (2012) Putting the brakes on continued androgen receptor signaling in castration-resistant prostate cancer. Mol Cell Endocrinol 360(1–2):68–75

    Article  Google Scholar 

  17. Tannock IF et al (2004) Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351(15):1502–1512

    Article  Google Scholar 

  18. Berthold DR et al (2008) Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. J Clin Oncol 26(2):242–245

    Article  Google Scholar 

  19. Georgi B et al (2014) Evolving therapeutic concepts in prostate cancer based on genome-wide analyses (review). Int J Oncol 45(4):1337–1344

    Article  Google Scholar 

  20. Sweeney CJ et al (2015) Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. N Engl J Med 373(8):737–746

    Article  Google Scholar 

  21. Attard G et al (2012) Clinical and biochemical consequences of CYP17A1 inhibition with abiraterone given with and without exogenous glucocorticoids in castrate men with advanced prostate cancer. J Clin Endocrinol Metab 97(2):507–516

    Article  Google Scholar 

  22. Danila DC et al (2010) Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancer. J Clin Oncol 28(9):1496–1501

    Article  Google Scholar 

  23. Ryan CJ et al (2015) Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol 16(2):152–160

    Article  Google Scholar 

  24. Sternberg CN et al (2014) Improved outcomes in elderly patients with metastatic castration-resistant prostate cancer treated with the androgen receptor inhibitor enzalutamide: results from the phase III AFFIRM trial. Ann Oncol 25(2):429–434

    Article  Google Scholar 

  25. Loriot Y et al (2015) Effect of enzalutamide on health-related quality of life, pain, and skeletal-related events in asymptomatic and minimally symptomatic, chemotherapy-naive patients with metastatic castration-resistant prostate cancer (PREVAIL): results from a randomised, phase 3 trial. Lancet Oncol 16(5):509–521

    Article  Google Scholar 

  26. A study of apalutamide (ARN-509) in men with non-metastatic castration-resistant prostate cancer (SPARTAN)

    Google Scholar 

  27. A study of JNJ-56021927 (ARN-509) and abiraterone acetate in participants with metastatic castration-resistant prostate cancer

    Google Scholar 

  28. Dy SM et al (2008) Evidence-based standards for cancer pain management. J Clin Oncol 26(23):3879–3885

    Article  Google Scholar 

  29. Saad F et al (2002) A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 94 (19):1458–1468

    Article  Google Scholar 

  30. Smith MR et al(2012) Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial. Lancet 379(9810):39–46

    Article  Google Scholar 

  31. Araujo JC et al (2012) Dasatinib combined with docetaxel for castration-resistant prostate cancer: results from a phase 1-2 study. Cancer 118(1):63–71

    Article  Google Scholar 

  32. Halperin EC et al (2007) Perez and Brady’s principles and practice of radiation oncology, 5. Aufl. Lippincott Williams & Wilkins

    Google Scholar 

  33. Taylor BS et al (2010) Integrative genomic profiling of human prostate cancer. Cancer Cell 18 (1):11–22

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Urologische Universitätsklinik Heidelberg, Im Neuenheimer Feld, 110, 69120, Heidelberg, Deutschland

    Svenja Dieffenbacher

  2. Urologische Universitätsklinik Heidelberg, Im Neuenheimer Feld, 110, 69120, Heidelberg, Deutschland

    Björn Georgi

  3. Urologische Universitätsklinik Heidelberg, Im Neuenheimer Feld, 110, 69120, Heidelberg, Deutschland

    Stefan Duensing

  4. Urologische Universitätsklinik Heidelberg, Im Neuenheimer Feld, 110, 69120, Heidelberg, Deutschland

    Markus Hohenfellner

Authors
  1. Svenja Dieffenbacher
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Björn Georgi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Stefan Duensing
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Markus Hohenfellner
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Svenja Dieffenbacher .

Editor information

Editors and Affiliations

  1. Urologische Universitätsklinik Heidelberg, Heidelberg, Germany

    Claudia Kesch

  2. Urologische Universitätsklinik Heidelberg, Heidelberg, Germany

    Markus Hohenfellner

Rights and permissions

Reprints and permissions

Copyright information

© 2018 Springer-Verlag GmbH Deutschland

About this chapter

Cite this chapter

Dieffenbacher, S., Georgi, B., Duensing, S., Hohenfellner, M. (2018). Multimodale Therapie des Prostatakarzinoms. In: Kesch, C., Hohenfellner, M. (eds) Aktuelles aus Klinik und Praxis der Urologie. WissenKompakt Medizin. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-55473-9_2

Download citation

  • DOI: https://doi.org/10.1007/978-3-662-55473-9_2

  • Published:

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-662-55472-2

  • Online ISBN: 978-3-662-55473-9

  • eBook Packages: Medicine (German Language)

Publish with us

Policies and ethics

Search

Navigation